technology

press releases

Date Title and Summary Additional Formats
Toggle Summary View HTML
Toggle Summary BOTHELL, Wash., June 02, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of migraine, and View HTML
Toggle Summary BOTHELL, Wash., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data from Phase 2b and Phase 1 clinical trials of ALD403 supporting development for the View HTML
Toggle Summary View HTML
Toggle Summary View HTML
Toggle Summary BOTHELL, Wash., July 18, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered View HTML
Toggle Summary BOTHELL, Wash., April 12, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced public offering of common stock, including 806,451 shares sold pursuant to the underwriters' exercise View HTML
Toggle Summary View HTML
Toggle Summary View HTML
Toggle Summary BOTHELL, Wash., April 06, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) , a clinical-stage biopharmaceutical company, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public View HTML